KUALA LUMPUR, Oct 13 (Bernama) -- Adagene Inc (Adagene) announced that it will present clinical data from phase 1b/2 studies of its anti-CTLA-4 antibody candidate, ADG116, at the upcoming Society for Immunotherapy of Cancer’s (SITC) Annual Meeting on Nov 8-12 in Boston.
The posters will summarise the comprehensive safety data for ADG116 with repeat dosing as monotherapy, as well as new data supporting its optimal dose selection in combination with two different anti-PD-1 therapies.
Additionally, data will show anti-tumour activity in warm and cold tumours, including details of a partial response with monotherapy and a complete response in combination therapy, which were both observed in tumour types where no anti-CTLA-4 therapy is approved.
According to a statement, both posters will be published on the company’s website in accordance with the SITC embargo policy on Nov 10, 2022.
Adagene Inc is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies.
-- BERNAMA
No comments:
Post a Comment